Braveheart Bio, Inc. (NASDAQ:BRVE) Given Average Rating of “Buy” by Analysts

Braveheart Bio, Inc. (NASDAQ:BRVE) has earned a consensus recommendation of “Buy” from the five research firms that are presently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have issued a report on the stock in the last year is $45.25.

BRVE has been the topic of several recent research reports. Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a research report on Saturday, August 15th. Stifel Nicolaus began coverage on shares of Braveheart Bio in a research note on Monday. They issued a “buy” rating and a $45.00 price target on the stock. Jefferies Financial Group began coverage on Braveheart Bio in a report on Monday. They set a “buy” rating and a $48.00 price target on the stock. Cantor Fitzgerald started coverage on Braveheart Bio in a research report on Monday. They set an “overweight” rating and a $40.00 price objective for the company. Finally, TD Cowen assumed coverage on Braveheart Bio in a report on Monday. They issued a “buy” rating for the company.

Insider Activity at Braveheart Bio

In related news, Director Orbimed Advisors Llc acquired 1,940,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $34,920,000.00. Following the completion of the purchase, the director directly owned 11,901,826 shares in the company, valued at $214,232,868. This trade represents a 19.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Erez Chimovits acquired 1,940,000 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the acquisition, the director directly owned 11,901,826 shares of the company’s stock, valued at approximately $214,232,868. This trade represents a 19.47% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 8,751,942 shares of company stock worth $157,534,956 in the last ninety days.

Braveheart Bio Price Performance

BRVE stock opened at $27.44 on Monday. Braveheart Bio has a 1 year low of $24.61 and a 1 year high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.